Overview

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Status:
Active, not recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase II MATCH treatment trial identifies the effects of copanlisib hydrochloride (copanlisib) in patients whose cancer has a genetic change called PIK3CA mutation. Copanlisib may stop the growth of cancer cells by blocking PIK3, a protein needed for cell growth. Researchers hope to learn if copanlisib will shrink this type of cancer or stop its growth.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)